Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review. 2022

Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
Transplant Department, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

Cytomegalovirus (CMV) disease caused by genetically resistant CMV poses a major challenge in solid organ transplant recipients, and the development of resistance is associated with increased morbidity and mortality. Antiviral resistance affects 5%-12% of patients following ganciclovir (GCV) therapy, but is more common in individuals with specific underlying risk factors. These include the CMV D+R- serostatus, type of transplanted organ, dose and duration of (Val)GCV ([V]GCV) prophylaxis, peak viral loads, and the intensity of immunosuppressive therapy. Guideline recommendations for the management of GCV resistance (GanR) in solid organ transplant recipients are based on expert opinion as there is a lack of data from controlled trials. Second-line options to treat GanR include foscarnet (FOS) and cidofovir (CDV), but these drugs are often poorly tolerated due to high rates of toxicity, such as renal dysfunction and neutropenia. Here, we report seven cardiothoracic transplant recipients with GCV resistance CMV infection from our centre treated with CMV immunoglobulin (CMVIG) +/- leflunomide (LEF) and reviewed the literature on the use of these agents in this therapeutic setting.

UI MeSH Term Description Entries
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D005916 Globulins A group of proteins that are salt-soluble and form a large fraction of BLOOD PROTEINS. There are three types of globulins, ALPHA-GLOBULINS, BETA-GLOBULINS, and GAMMA-GLOBULINS, which are distinguished from one another by their degree of electrophoretic mobility. Globulin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077339 Leflunomide An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS. Arava,HWA 486,HWA-486,N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide,SU101,HWA486
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D015774 Ganciclovir An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. BIOLF-62,BW-759,Cytovene,Ganciclovir Sodium,Ganciclovir, Monosodium Salt,Gancyclovir,RS-21592
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral
D066027 Transplant Recipients Individuals receiving tissues or organs transferred from another individual of the same or different species, or from within the same individual. Recipient, Transplant,Recipients, Transplant,Transplant Recipient

Related Publications

Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
June 1989, Transplantation proceedings,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
November 2001, Transplantation,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
October 1995, Transplantation proceedings,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
March 2004, Transplantation,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
October 1994, Transplantation proceedings,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
October 1992, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
January 1982, Developments in biological standardization,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
January 2008, Clinical transplantation,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
April 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Karthik Santhanakrishnan, and Nizar Yonan, and Kapil Iyer, and Paul Callan, and Mohamed Al-Aloul, and Rajamiyer Venkateswaran
October 1995, Transplantation proceedings,
Copied contents to your clipboard!